ArticleJournal, genetic engineering & biotechnology2025
Targeting cholinergic dysfunction in Alzheimer's disease: Development of next-generation galantamine derivatives.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) presents a significant and unmet medical need. Acetylcholinesterase (AChE) enzymes are key contributors to AD pathogenesis, instigating a cholinergic deficit and subsequent neurodegenerative progression, leading to neuronal loss and cognitive decline. This study leverages in silico methods to elucidate the structure-activity relationships (SAR) governing binding interactions and affinity between human AChE (hAChE, PDB ID: 4EY6) and potential novel ligands. Galantamine, a cornerstone cholinergic therapy for AD, serves as the template for the design of structurally diverse galantamine analogs. Employing rigorous molecular docking simulations and molecular dynamics simulations, these analogs exhibit promising potential for modulating the cholinergic system and mitigating cognitive dysfunction associated with AD. Our findings demonstrate the efficacy of computational drug design in developing superior galantamine analogs with enhanced target selectivity and potentially improved therapeutic profiles for AD patients, aiming to achieve superior cognitive outcomes and improved quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.